Program

The Organizing Committee proudly presents the tentative workshop program:

 

Wednesday 13 September 2017

9:00Workshop Opening
Etienne Chatelut, PharmD, PhD and Howard Gurney, MB, BS, FRACP
9:15Opening Lecture: Inter- and Intravariability in PK
Mark Ratain, MD - University of Chicago, USA
(t.b.c.)
 
  Session 1: PK of Mab: target therapy and checkpoint inhibitors; choice of the dose
  Chairs:
9:45ADA-formation and its Effect on Mab PK
Maria-Jesus Garrido, PhD - University of Navarra, Spain
10:15PK and PKPD Considerations for Dose Selection in the Development of Pembrolizumab
Dinesh de Alwis, PhD - Merck Research Laboratories, USA
10:45Discussion
 
11:00Coffee break
 
  Session 2: TDM for targeted therapies
  Chairs:
11:30Model-based TDM for Oncology Drugs
Ron Keizer, PharmD, PhD - InsightRX, USA
12:00Physiologically Based PK Model vs. Population PK Approach during Drug Development
Italo Poggesi, ChemD - Janssen-Cilag, Italy
12:30Discussion
 
12:45Group Picture & Lunch
14:00Guided Poster Tour
 
  Session 3: Drug Transporters / Epigenetic and ADME
  Chairs:
14:45Drug transporters as a PK or PD covariate for individual dosing
Alex Sparreboom, PhD - The Ohio State University, USA (t.b.c.)
15:15DNA-Methylation of ADME Gene
Matthias Schwab, MD - Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
15:45Discussion
 
16:00Coffee break
 
  Session 4: Abstract driven presentations / clinical cases
  Chairs:
16:30Abstract - driven presentations
17:30Abstract - driven presentations / clinical cases
18:00Discussion
 
18:15End of Plenary Session: Welcome Reception & Poster Viewing
 
19:30Workshop Dinner
 

Thursday 14 September 2017

 
  Session 5: Optimal Study Design
  Chairs:
8:30Optimal design – potential application in oncology drug development and clinical practice
Andrew Hooker, PhD - Uppsala University, Sweden
9:00Phase 1 design including PK issues
Jan Schellens, MD - Netherlands Cancer Institute, The Netherlands (t.b.c.)
9:30Abstract - driven presentations
10:00Panel Discussion
 
10:30Coffee break
 
  Session 6: Epigenetic Therapy / Special Populations / Interactions
  Chairs:
11:00Invited Lecture on Pediatrics
Francesco Pignatti, MD - European Medicines Agency - United Kingdom (t.b.c.)
11:30Abstract - driven presentations
12:30Panel Discussion
 
13:00Closure of the Workshop

The following experts have confirmed their contribution to the workshop: